Gov. Gavin Newsom’s ambitious plan to produce a cheap, generic insulin for the 3.2 million Californians with diabetes is behind the schedule he announced and unlikely to make it to market for several years, industry experts say.
Civica, Inc., the nonprofit drug manufacturer contracted to produce insulin for California, has not started clinical trials or applied for approval from the federal Food and Drug Administration, both of which are likely to take more than a year to complete.
Continue reading for FREE
This is NOT a paywall. We just want to make sure you’re a human. Sign in to read this story and receive the weekly roundup in your inbox.
Success! Your account was created and you’re signed in.
Please visit My Account to manage your account.
